CAMBRIDGE, Mass.–Immuto Scientific has reported preclinical research identifying 16 potential cell-surface targets for new antibody-based treatments for KRAS-mutant colorectal cancer, using its artificial intelligence-enabled structural surfaceomics platform.
The findings, developed in collaboration with the University of Wisconsin-Madison, are being presented at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
The research examined patient-derived models of KRAS-mutant colorectal cancer and compared them with healthy colon organoids to identify differences in protein abundance, cell-surface presence and protein structure.
Researchers identified distinct structural characteristics in the cancer models, including disease-associated features shared across samples from different patients.
By combining measurements of protein abundance, structural characteristics and cell-surface location, Immuto prioritized 16 potential therapeutic targets for further investigation.
The findings could provide new opportunities for developing antibody-based medicines designed to recognize structural features associated with colorectal cancer cells.
“By identifying structural features shared across KRAS-mutant colorectal cancer models, we uncovered new opportunities for more precise antibody-based medicines,” said Faraz A. Choudhury, Ph.D., Co-Founder and CEO of Immuto Scientific.
“In these KRAS-mutant colorectal cancer models, our platform revealed shared disease-associated structural features despite differences between individual patients. This work has already led to a new internal program in our pipeline, demonstrating how structural surfaceomics can translate disease-specific biology into therapeutic opportunities.”
The study also examined the limitations of traditional approaches that rely primarily on measuring protein abundance to identify potential cancer treatment targets.
Researchers found that several established targets showed limited differences between cancerous and healthy colon models when evaluated solely by protein abundance.
However, incorporating information about protein structure revealed additional distinctions that could help identify targets more specific to cancer cells.
Immuto’s structural surfaceomics technology is designed to analyze the structural characteristics of proteins on cell surfaces, allowing researchers to investigate disease-associated changes that may not be apparent through conventional protein analysis.
The company said the findings have already contributed to the development of a new internal therapeutic program focused on targets identified through its platform.
The research remains at the preclinical stage, and the 16 identified targets will require further investigation to determine their potential for developing effective cancer treatments.


